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Background: Plasma phospholipid transfer protein (PLTP) transfers lipids between donors and acceptors (e.g., from
HDL to VLDL) and modulates lipoprotein composition, size, and levels. No study has reported an assessment of the
effects of PLTP on blood clotting reactions, such as reflected in thrombin generation assays, or on the association
of venous thrombosis (VTE) risk with PLTP activity.
Methods: The in vitro effects of PLTP on blood coagulation reactions and the correlations between plasma PLTP
activity levels and VTE were studied.
Results: Recombinant (r) PLTP concentration-dependently inhibited plasma thrombin generation and factor
XII-dependent kallikrein generation when sulfatide was used to stimulate factor XII autoactivation in plasma.
However, rPLTP did not inhibit thrombin generation in plasma induced by factor XIa or tissue factor, implicating
an effect of PLTP on contact activation reactions. In purified systems, rPLTP inhibited factor XII autoactivation
stimulated by sulfatide in the presence of VLDL. In surface plasmon resonance studies, purified factor XII bound
to immobilized rPLTP, implying that rPLTP inhibits factor XII-dependent contact activation by binding factor XII
in the presence of lipoproteins. Analysis of plasmas from 40 male patients with unprovoked VTE and 40 matched
controls indicated that low PLTP lipid transfer activity (≤25th percentile) was associated with an increased risk of
VTE after adjustment for body mass index, plasma lipids, and two known thrombophilic genetic risk factors.
Conclusion: These data imply that PLTP may be an antithrombotic plasma protein by inhibiting generation of
prothrombotic factor XIIa in the presence of VLDL. This newly discovered anticoagulant activity of PLTP merits
further clinical and biochemical studies.
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The blood coagulation system is triggered by either the
intrinsic or extrinsic pathway and involves sequential
enzymatic activations of serine protease zymogens en-
hanced by non-enzymatic cofactors, factors Va and VIIIa,
resulting in generation of thrombin [1, 2]. Thrombin
generation is central to the regulation of hemostasis
and thrombosis and to the pathogenesis of cardiovascular
disease and venous thrombosis. The intrinsic pathway is
triggered by contact activation. Recent studies using mouse
thrombosis models suggest that the intrinsic pathway is* Correspondence: dhiroshi@scripps.edu
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(http://creativecommons.org/publicdomain/zeessential for pathological thrombus formation in both
the arterial [3–7] and venous systems [7]. The “contact
activation” of plasma involves 3 zymogens, factor XII,
factor XI and prekallikrein, plus a non-enzymatic cofactor,
high molecular weight kininogen, that participate in a set
of interrelated proteolytic activation reactions [4, 8–15].
During the initial stages of contact activation, factor XII
and prekallikrein participate in reciprocal proteolysis in
which factor XIIa activates prekallikrein to kallikrein,
which in turn converts factor XII into factor XIIa. Activa-
tion of factor XII can be enhanced by autoactivation of
zymogen factor XII by the active form α-factor XIIa.
These reactions are accelerated by negatively charged
surfaces (e.g., kaolin, sulfatides, and dextran sulfate).article distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver
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coagulant and anticoagulant reactions [16, 17]. Further-
more, dyslipidemia and dyslipoproteinemia are associated
with hypercoagulability and venous thromboembolism
(VTE) [16, 17]. The lipid transfer protein, cholesteryl ester
transfer protein (CETP), which carries and transfers lipids
to modulate plasma lipoprotein levels, can exert pro-
coagulant activity by enhancing prothrombinase activity
in purified systems [18]. Furthermore, plasma CETP
mass level was correlated with relative hypercoagulabil-
ity of plasma independent of high density lipoprotein
(HDL) levels. Although molecular mechanisms for CETP
procoagulant activity remain unclear, we hypothesized
that other lipid transfer proteins can also affect blood
coagulation.
Plasma phospholipid transfer protein (PLTP), a homolog
of CETP, circulates in plasma and facilitates the transfer of
phospholipids and cholesterol among lipoproteins [19–27].
It can mediate the conversion of HDL into larger and
smaller particles [28, 29] and generate pre-β HDL in the
process [30]. PLTP also transfers phospholipids from very
low density lipoprotein (VLDL) to HDL by PLTP shuttling
from HDL to VLDL particles [31]. In clinical studies, high
PLTP activity was reported to be associated with the in-
creased risk of coronary artery disease [32, 33], notably
in statin-treated patients [34]. In contrast, low PLTP
activity was reported to be associated with peripheral
atherosclerosis [35], suggesting that the relationship of
plasma levels of PLTP activity to cardiovascular risk is
controversial [32–38]. No study has reported an assess-
ment of the effects of PLTP on blood clotting reactions,
such as reflected in thrombin generation assays, or on
the association of VTE risk with PLTP activity.
Here we report that PLTP can inhibit sulfatide-induced
contact activation of thrombin generation, that factor XII
binds directly to PLTP, and that low plasma PLTP activity
levels may be associated with VTE risk.
Methods
Materials
Fatty acid-free bovine serum albumin (BSA) was pur-
chased from Calbiochem (San Diego, CA). Human factor
XIa and corn trypsin inhibitor were from Hematologic
Technologies Inc. (Essex Junction, VT). Human factor
XII, prekallikrein and kallikrein were from Enzyme Re-
search Laboratories (South Bend, IN). Human α-factor
XIIa was from Aniara (Mason, OH). VLDL was purchased
from Intracel (Frederic, MD). Sulfatide was obtained from
Matreya (Pleasant Gap, PA). Kaolin was from Fisher
Scientific Inc. (Pittsburgh, PA) and dextran sulfate was
from GE Healthcare (Parsippany NJ). Innovin was from
DADE (BioMerioeux). Chromogenic substrate S2302
and fluorogenic substrate I-1140 were obtained from
Chromogenix (Franklin, OH) and Bachem BioscienceInc. (King of Prussia, PA), respectively. Normal human
pooled plasma was prepared using blood obtained from
20 adult healthy donors (10 males and 10 females) by
routine venipuncture from the Scripps General Clinical
Research Center’s (GCRC) blood donation program
after an overnight fast. Blood was mixed with 0.129 M
sodium citrate at 1:9 ratios. Plasma was prepared by cen-
trifugation at 2,000 × g for 20 min at room temperature
from each donor and pooled. The pooled normal human
plasma was stored at −80 °C. Blood from VTE patients
was collected in the GCRC at least 3 months after VTE
diagnosis and after a 12 h fast.
Recombinant (r) PLTP
Recombinant wild-type PLTP was made and characterized
as full length molecules as reported [29, 39]. Briefly, rPLTP
was isolated by Ni2+-nitrilotriacetic acid resin column chro-
matography from serum-free conditioned culture medium
collected from baby hamster kidney cells transfected with a
His-tagged human rPLTP cDNA using methotrexate as
selection agent. The isolated rPLTP fractions were
assayed for phospholipid transfer activity and evaluated
for purity by SDS-PAGE. The concentration of rPLTP
was determined by the absorbance at 280 nm. rPLTP
was stabilized by adding phosphatidylcholine vesicles in
Tris-buffered saline (TBS) containing 0.05 M Tris, 0.15 M
NaCl, pH 7.4. The same buffer containing the same con-
centration of phosphatidylcholine vesicles without rPLTP
was used as control for activity assays.
Preparation of sulfatide vesicles
Sulfatide vesicles were prepared by sonication and
stored up to two days. Briefly, 1 mg/ml bovine sulfatide
in TBS was sonicated 5 times for 30 s with 1 min intervals
using the ultrasonic processor XL (Heat System, Inc.,
Farmingdale, NY) under the flow of N2.
Thrombin generation assay in plasma
Plasma thrombin generation assays were performed as
described with some modifications [40]. Pooled normal
human plasma (30 μl) was incubated with various rPLTP
concentrations for 15 min at 37 °C. Then, tissue factor
(Innovin, final 4 pM) or sulfatide vesicles containing
30 mM CaCl2 and fluorogenic thrombin substrate solution
(I-1140) was added to the plasma mixture (total 110 μl) to
initiate coagulation activation. In factor XIa (0.13 nM,
final) -induced thrombin generation assays, corn trypsin
inhibitor (50 μg/ml, final) was also pre-incubated with
plasma. Thrombin generation was followed continuously
using SPECTRAmax GEMINI XS fluorometer (Molecular
Devices, Sunnyvale, CA) with excitation and emission
wavelengths set at 360 and 460 nm, respectively. The first
derivative of fluorescence versus time was used to produce
thrombin generation curves.
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The generation of plasma kallikrein in the presence of
sulfatide was determined as described with some modifi-
cations [8]. Briefly, plasma (1:100, final dilution) was in-
cubated with PLTP for 15 min at room temperature,
followed by the addition of sulfatide (0.5 μM, final) and
then incubated at various times. Kallikrein amidolytic
activity was measured by hydrolysis of the kallikrein
amidolytic substrate, S2302 (0.4 mM, final). Soy bean
trypsin inhibitor (500 μg/ml, final), which inhibits kallikrein
activity, inhibited S2302 hydrolysis in this assay system by
approximately 95 %, whereas corn trypsin inhibitor, which
specifically inhibits factor XIIa, inhibited S2302 hydrolysis
by 5 % (data not shown). These showed that the S2302
hydrolysis by contact phase activation in this plasma
assay system mainly reflects kallikrein generation rather
factor XIIa generation due to the different reactivities
of kallikrein and factor XIIa with the substrate [13].
Factor XII activation in purified protein system
For factor XII autoactivation assays, factor XII (0.1 μM,
final) was pre-incubated with rPLTP in the presence or
absence of VLDL (25 μg protein/mL, final) for 15 min
at room temperature, and then sulfatide vesicles (0.5 μM,
final) were added to start autoactivation of factor XII.
S2302 (0.4 mM, final) was added at various time points and
the amidolytic activity of factor XIIa was measured [8, 9].
Activation of factor XII by kallikrein was measured as
described [10]. The reaction mixture containing factor
XII (0.1 μM, final) with or without rPLTP (5 μg/mL,
final) in the presence or absence of VLDL (25 μg pro-
tein/mL, final) was pre-incubated for 15 min at 37 °C,
followed by the addition of kallikrein (0.4 nM, final)
and incubated for optimal time. The reaction was
stopped by adding soybean trypsin inhibitor (500 μg/ml
final) to block kallikrein. The generated factor XIIa ac-
tivity was measured as amidolytic activity for S2302
(0.4 mM, final).
Prekallikrein activation by factor XIIa
Activation of prekallikrein by factor XIIa was measured
as described [12]. The reaction mixture containing pre-
kallikrein (0.25 μM, final) with or without rPLTP (5 μg/
mL, final) in the assay buffer was pre-incubated in the
presence or absence of VLDL (25 μg protein/mL, final)
for 15 min at 37 °C, followed by the addition of factor
XIIa (0.1 nM, final) and incubated for optimal times.
The kallikrein activity generated was measured as ami-
dolytic activity for S2302 (0.4 mM, final).
Factor XII binding to PLTP
Binding was assessed by surface plasmon resonance
(SPR) analysis using a BIAcore 3000 biosensor system.
An anti-His tag monoclonal antibody was covalentlyimmobilized on the carboxymethylated dextran (CM5)
sensor chip (BIAcore) using amine coupling chemistry
according to the manufacturer’s instructions. A nonreactive
mouse IgG was used as a control for nonspecific binding.
rPLTP with a C-terminal His-tag (100 μg/ml) was diluted
in 50 mM Hepes, 150 mM NaCl, and 5 mM CaCl2
(pH 7.4) and injected at a flow rate of 10 μL/min with
10 min contact time generating a response. Then, each
concentration of factor XII was injected in this buffer for
1.5 min at a flow rate of 5 μL/min. After each Factor XII
sensorgram was obtained, the His tag-antibody surface was
regenerated with 10 mM glycine/HCl, pH 2.5, and a new
injection of His-tag PLTP was used to regenerate the
surface. Any influence of mass transport effects was
discounted from the results of binding and dissociation
at different flow rates. Data analysis was performed by
using BIAevaluation software 3.0 (BIAcore). The associ-
ation and dissociation phases of all ‘sensorgrams’ were
fitted globally. Rate constants for association (ka) and
dissociation (kd) were obtained by globally fitting the
data from five to six injections of factor XII (0–750
nM) by using the BIAevaluation software version 3.2,
using the simple Langmuir binding model.
VTE study group
The Scripps Venous Thrombosis Registry is an ongoing
case–control study of risk factors for VTE as described
[41]. Inclusion criteria for this study included age at
thrombosis < 55 years old, >3 months since diagnosis
of acute thrombosis, a life expectancy of at least 3 years
and no lipid lowering medications or cancer. Age
matched (±2 years) healthy male controls were recruited
through the GCRC blood donation program at Scripps.
The protocol was approved by the Institutional Review
Board of Scripps Clinic and subjects provided written
informed consent. Forty of 49 VTE patients (82 %) pre-
sented with idiopathic VTE, defined as events that did
not occur within 90 days after surgery, trauma, or major
immobilization. In this study, male idiopathic VTE
patients (n = 40) and controls (N = 40) were analyzed for
PLTP activity and mass (Additional file 1: Table S1).
Clinical analytes
Serum lipid profile data were obtained from the routine
clinical lab using standard techniques.
Lipoprotein subclass particle concentrations were
measured by Nuclear Magnetic Resonance Spectroscopy
(NMR) at LipoScience, Inc (Raleigh,NC) [41]. PLTP ac-
tivity (total plasma activity) and mass were determined
as described [23, 26].
Statistical analysis
Data for VTE patients and controls was compared for
median values using the Mann–Whitney test using Prism™













































Fig. 1 Inhibition of thrombin generation by rPLTP. Normal pooled
human plasma was mixed with various concentrations of rPLTP, and
thrombin generation was initiated by adding the following procoagulant
stimuli with 30 mM CaCl2: a sulfatides (20 μM); b factor XIa (0.13 nM
final) plus corn trypsin inhibitor; or c tissue factor. Concentrations of
rPLTP used with different procoagulant stimuli were: a 0, 5, 10, 20, 40
and 80 μg/ml corresponding to the lines from left to right; b 0, 5 (top
two lines which overlap each other), 10 and 40 μg/ml corresponding to
the lines from top to bottom; and c 0, 5 and 10 (three lines which
overlap each other), and 40 μg/ml of rPLTP (bottom line)
Deguchi et al. Thrombosis Journal  (2015) 13:24 Page 4 of 94.0 software (Graph Pad Software Inc., San Diego, CA).
Odds ratios for VTE were determined with a logistic re-
gression model using Minitab software. The difference
was considered significant when p was < 0.05.
Results
Effects of rPLTP on sulfatide-induced plasma thrombin
generation
When added to plasma in increasing amounts, rPLTP
markedly reduced the total amount of thrombin generation
and prolonged the lag time for thrombin generation in
plasma activated by sulfatides (Fig. 1a). In contrast, rPLTP
had no effect or only a very slight effect on factor XIa-
induced or tissue factor-induced thrombin generation in
plasma (Figs. 1b and c). This suggests that rPLTP signifi-
cantly inhibits the factor XII-dependent contact activation
reactions but not the intrinsic or extrinsic coagulation
pathways activated by factor XIa or tissue factor.
Effect of increasing sulfatide concentration on inhibition
of thrombin generation in plasma by rPLTP
To study if the effect of rPLTP is due to interactions of
rPLTP with sulfatide, the effect of rPLTP was tested
under various concentrations of sulfatide (2 μM, 20 μM
and 100 μM). The ability of rPLTP to inhibit thrombin
generation was not neutralized or significantly altered by
increasing the amounts of sulfatide (e.g., from 2 μM to
100 μM) (Fig. 2), indicating that the major effect of
PLTP was independent of sulfatide concentration. Besides
sulfatides, other negatively charged surfaces (e.g., kaolin,
dextran sulfate, etc.) also stimulate contact activation.
When contact activation was stimulated by kaolin or
dextran sulfate, rPLTP did not inhibit thrombin generation
in plasma (Additional file 1: Figure S1).
Effect of rPLTP on sulfatide-induced kallikrein generation
in plasma
To study the effect of rPLTP on contact activation reac-
tions, the sulfatide-induced activation of prekallikrein/factor
XII in plasma was evaluated at various time points. In the
assay system employed, contact activation was monitored
by kallikrein generation. In controls, rPLTP (0–20 μg/ml)
did not directly affect the kallikrein amidolytic activity to-
wards the chromogenic substrate S2302 (data not shown).
rPLTP delayed generation of plasma kallikrein activity by
sulfatides in plasma (Fig. 3a) and did so in a concentration-
dependent fashion (IC50 = 0.69 μg/ml) (Fig. 3b). These data
show that rPLTP inhibits contact phase activation in the
coagulation system.
Effect of rPLTP on contact phase activation
Contact phase activation in the coagulation system is en-
hanced by factor XII autoactivation and by the reciprocal
activations of factor XII by kallikrein and of prekallikreinby factor XIIa. When the effect of rPLTP on contact acti-
vation reactions was studied in assays containing only
purified protein components, rPLTP did not affect factor







































Fig. 2 Inhibition of thrombin generation by rPLTP at various
concentrations of sulfatide. Normal pooled human plasma was
mixed with rPLTP or control buffer and thrombin generation was
initiated by adding procoagulant sulfatide with 30 mM CaCl2 at
the following levels: a 2 μM; b 20 μM; or c 100 μM. The rPLTP


















































Fig. 3 Inhibition of sulfatide-induced kallikrein generation by rPLTP in
plasma. a The time course of inhibition of sulfatide-dependent kallikrein
generation by PLTP is shown as kallikrein amidolytic activity (S2302). The
rPLTP concentration was 0 (○) or 5 μg/ml (●). b The rPLTP dose response
for inhibition of sulfatide-dependent kallikrein generation by rPLTP in
plasma is shown based on kallikrein activity determined at 6 min after
kallikrein generation was initiated by adding (0.5 μM) sulfatides
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activation by kallikrein, or prekallikrein activation by
factor XIIa (Additional file 1: Figure S2, A, B, and C,
respectively). However, when VLDL was added into the
purified reaction component mixture, rPLTP inhibited
factor XII autoactivation (Fig. 4a) in a concentration-
dependent fashion (IC50 = 1.2 μg/ml) (Fig. 4b). NeitherFactor XII activation by kallikrein nor prekallikrein
activation by factor XIIa was affected by rPLTP in the
absence or presence of VLDL (Additional file 1: Figure S3
A and B). The amidolytic activity of FXIIa or kallikrein
towards S2302 was not inhibited by PLTP even in the
absence or presence of VLDL (data not shown).
rPLTP binding to factor XII
SPR was used to study the binding of factor XII to
rPLTP. Factor XII bound to immobilized rPLTP whereas
Fig. 4 Inhibition of sulfatide-stimulated FXII autoactivation by rPLTP
in the presence of VLDL. a The time course of inhibition of sulfatide-
stimulated factor XII autoactivation by rPLTP was determined when
factor XII (0.1 μM, final) was pre-incubated with rPLTP (5 μg/mL) in
the presence of VLDL (25 μg/ml protein, final) for 15 min at room
temperature, and sulfatide vesicles (final 0.5 μg/ml) were added to
start autoactivation of factor XII. Then, S2302 was added at various
time points and the amidolytic activity was measured at different
time points. The rPLTP concentration was 0 (○) or 5 μg/ml (●). b The
dose–response for rPLTP inhibition of sulfatide-stimulated factor XII
autoactivation by rPLTP was determined as in panel (a) and data for






















Fig. 5 Binding of Factor XII to rPLTP using SPR. SPR was used to
monitor binding of factor XII (250–750 nM) to immobilized rPLTP.
Sensorgrams represent the binding of factor XII (from top to bottom
at 750, 625, 500, 375, 250 nM, as indicated. In controls, purified
Factor XI (500 nM) (dotted line) did not exhibit any binding to
immobilized rPLTP
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detected by SPR (Fig. 5). Based on the data analysis, rate
constants kon and koff for binding of factor XII to rPLTP
and its apparent Kd were 0.31 × 105 (1/Ms), 60 × 10−4
(1/s) and 190 nM, respectively.Association of venous thrombotic disease with PLTP
activity and mass
Because rPLTP can inhibit thrombin generation in
plasma, we postulated that low plasma levels of PLTP
may be linked to VTE. In a pilot study of subjects from
the Scripps VTE Registry, we assessed whether low
levels of plasma PLTP are associated with VTE risk.
There was no significant difference in the median values
of PLTP activity or PLTP mass levels in 40 adult male
VTE patients compared to matched controls (p = 0.57
and 0.59, respectively) (data not shown). When the
quartile-based odds ratio (OR) for the association of
VTE with PLTP activity was calculated by comparing
quartile 1 (lowest PLTP) with quartiles 2–4 (Table 1), a
low level of PLTP activity was not statistically signifi-
cantly associated with increased VTE risk although the
OR was 2.2 (95%CI: 0.78-5.9) (Table 1, model I). Some
plasma parameters which may be associated with both
PLTP level and VTE risk, namely BMI and HDL-C
(Additional file 1: Table S1) (23), and some other lipids
possibly linked to procoagulant activities which may be
altered by PLTP were used for adjustment of the OR.
When adjusted for BMI and HDL-C, the OR for low
PLTP activity was 2.7 (95%CI: 0.91-7.8, p = 0.07)
(Table 1, model II), and further adjustment for LDL-C
and triglyceride (TG) improved the OR to 5.2 (95%CI:
1.5-19, p = 0.01) (Table 1, model IV). Particularly signifi-
cant was the finding that the low PLTP activity level was
highly significantly associated with the risk of VTE with
an OR = 12 (95%CI: 2.4-56, p = 0.002) after further ad-
justment for the known VTE risk factors, FV Leiden and
prothrombin nt20210A (Table 1, model V). When VLDL
particle concentrations measured by NMR was used for
the correction instead of TG, the ORs were similar to
the values with triglyceride (OR = 5.3 (95%CI: 1.5-19) for
Table 1 Quartile-based Odds Ratio (OR) for association of low PLTP activity (≤25th percentile)
PLTP activity PLTP mass
Model and adjustments OR (95%CI) p OR (95%CI) p
I. No adjustment 2.2 (0.78-5.9) 0.15 1.3 (0.46-3.8) 0.59
II. BMI + HDL 2.7 (0.91- 7.8) 0.07 0.53 (0.14-2.1) 0.55
III. II + FV Leiden + prothrombin nt20210A 3.5 (1.1-12) 0.04 0.49 (0.1-1.8) 0.37
IV II + LDL-C + TG 5.2 (1.5-19) 0.01 0.84 (0.23-3.0) 0.79
V. III+ LDL-C + TG 12 (2.4-56) 0.002 0.62 (0.15-2.6) 0.52
The odds ratios (OR) for unprovoked VTE with low levels (≤25th percentile) of PLTP activity and PLTP mass are shown. Models were adjusted by variables as
indicated, including BMI, HDL-C, LDL-C and TG which were used as continuous values and factor V Leiden and prothrombin nt20210A
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spectively). The high PLTP levels (>75 percentile) was
not protective against VTE (OR = 1.4 (95%CI: 0.55-3.8),
p = 0.53) even after adjustment described above (OR =
0.75 (95%CI: 0.23-2.5) for model IV and OR = 0.65
(95%CI: 0.17-2.5) for model V, respectively). PLTP mass
was not associated with the risk of VTE based on
quartile-based OR analysis in any of the models summa-
rized in Table 1.
Discussion
In this study we showed that a recombinant plasma
protein, rPLTP, can inhibit sulfatide-induced thrombin
generation and contact activation in plasma, implying
that it may function as an anticoagulant factor where
contact activation is involved. This activity of rPLTP
was not apparent when thrombin generation in plasma
was triggered by factor XIa or tissue factor, implying a
direct effect of rPLTP on contact activation reactions.
Factor XII is the key enzyme for contact activation [1–7]
and, indeed, we found that factor XII binds directly to
rPLTP, thereby providing a starting point for mechanistic
studies for the actions of rPLTP.
Interestingly, rPLTP did not inhibit contact activation
in plasma stimulated by two other negatively charged
activators of the contact system, dextran sulfate and
kaolin, further implying that the anticoagulant actions
of rPLTP were not due to a nonspecific blocking of
negative charges. These findings might be supported by
reports that mechanisms responsible for surface activa-
tion triggered by different negatively charged molecules
(e.g., sulfatide and kaolin) differ from each other as
regards the molecular interaction with the contact factors
[11, 14]. However, the details for the mechanistic relations
of PLTP to surface materials for contact activation of
coagulation including other naturally occurring negatively
charged surfaces effect (e.g., misfolded proteins, and poly-
phosphates) need to be evaluated in future studies.
The requirement of VLDL, which also could provide
surface for contact pathway of coagulation system [42],
for the inhibition of sulfatide-induced autoactivation offactor XII by rPLTP in purified protein reaction mixtures
may reflect direct or indirect effects of VLDL on factor
XII and/or rPLTP. Recent work shows that a significant
fraction of PLTP is bound to VLDL in plasma [39], so
the ability of rPLTP to inhibit sulfatide-induced contact
activation in plasma or factor XII autoactivation likely
reflects actions of a PLTP●VLDL complex in plasma.
Extensive and detailed mechanistic studies using rPLTP,
factor XII and α-factor XIIa plus VLDL and many pro-
teins that associate with VLDL [43] would be needed
for studies to clarify details and elucidate the structural
basis for the effects of these molecules on contact activation
or factor XII autoactivation. Further, other lipoproteins (i.e.,
HDL and LDL), which were not tested here, could also
possibly contribute to the anticoagulant activity of PLTP.
Binding studies using purified proteins show direct
interactions between factor XII and PLTP. For this
protein-protein interaction, the apparent Kd value of
190 nM is below the plasma level of factor XII which
is 300 nM [44] but above the plasma level of PLTP at
25 nM [19]. Perhaps reflecting this modest value of
apparent Kd, PLTP alone does not inhibit sulfatide-
induced factor XII autoactivation in purified reaction
systems. However, when VLDL was added to the purified
system, PLTP does inhibit Factor XII autoactivation,
showing additional plasma components are needed. Thus,
because VLDL particles carry many associated proteins in
addition to PLTP [43], we speculate that the whole VLDL
particles or one or more proteins in the VLDL interactome
enhances affinity of PLTP for factor XIIa which at very
low levels is responsible for triggering factor XII auto-
activation. Additionally, factor XII conformational changes
induced by sulfatide or zinc ions [14] might influence the
affinity of factor XIIa for PLTP. However, mechanisms for
inhibition of factor XII autoactivation by PLTP in plasma
are not completely clear and they need further clarifica-
tions including the potential influences of VLDL, sulfatide,
or zinc ions on factor XIIa-PLTP binding interactions.
Factor XII is not required for normal hemostasis in
man or various animals. However, studies of thrombosis
injury models in mice genetically deficient in factor XII
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ation via the intrinsic coagulation pathway can significantly
contribute in vivo to fibrin formation and thrombosis in-
cluding a pulmonary embolism model [3–7]. This concept
plus the ability of PLTP to inhibit thrombin generation in
plasma led us to assay PLTP activity and mass in plasmas
of a young adult male VTE cohort that we have previously
described [23, 41]. The initial analysis of our data without
any adjustments for variables failed to show any association
of plasma PLTP activity and mass levels with VTE risk.
However, a very significant association between low
PLTP activity and VTE became apparent after making
adjustments for various lipoprotein levels (Table 1,
models IV and V) or by analyzing separately the sub-
group of normolipidemic patients (Additional file 1:
Figure S4). It appears that levels of plasma lipopro-
teins, which are indeed related to PLTP-mediated
phospholipid transfer activity [23], can mask the asso-
ciation of PLTP activity with VTE risk. Overall, our
finding here is consistent with the concept that active
PLTP molecules, putatively in VLDL●PLTP complexes
[43], contribute to the multiple, highly varied anti-
thrombotic activities of plasma. One notes that major
limitations of this pilot VTE study include the low
number of subjects, the age of subjects under 55 years
old, and the absence of female cohorts.
Factor XII-dependent contact activation not only might
contribute in vivo to fibrin formation and excessive
thrombosis including pulmonary embolism model [3–7]
but also might contribute to inflammation and pathologies
via bradykinin formation and complement activation [5, 6,
45]. Thus, inhibition of contact activation mediated by
PLTP might inhibit not only thrombosis but also inflam-
matory processes stimulated or supported by contact
activation. In this regard, it is interesting that PLTP was
shown to exert anti-inflammatory activities [46, 47], al-
though no information relating PLTP’s anti-inflammatory
actions to any pro-inflammatory actions due to contact
activation have been described.Conclusions
We found that PLTP is an inhibitor of sulfatide-initiated
factor XII-dependent thrombin generation by inhibiting
factor XII autoactivation and that VLDL appears to con-
tribute to this activity of PLTP. After adjustments for
two thrombophilic genetic risk factors and for lipoprotein
and lipid parameters known to be affected by plasma
PLTP activity, low plasma PLTP activity was very signifi-
cantly associated with increased risk of VTE in a small
pilot study of young adult normolipidemic males. Both the
functionally significant interactions between PLTP and
factor XII and the relationship between PLTP activity and
VTE merit further detailed investigations.Additional file
Additional file 1: Table S1. Scripps Registry VTE Study population.
Figure S1. PLTP Inhibition of thrombin or kallikrein generation stimulated
by kaolin or dextran sulfate in plasma. Normal pooled human plasma
(30 μl) was mixed with rPLTP (0 (○) or 40 μg/ml (●), respectively), and
thrombin generation was initiated by adding kaolin (0.25 mg/ml) (A) or
dextran sulfate (25 μg/ml) (B) with 30 mM CaCl2. Figure S2. Absence of
inhibition by rPLTP of sulfatide-stimulated FXII autoactivation or of factor
XII activation by kallikrein or of prekallikrein activation by factor XIIa in the
absence of VLDL in purified systems. (A) Time course of sulfatide-stimulated
factor XII autoactivation. (B) Time course of factor XII activation by kallikrein.
(C) Time course of prekallikrein activation by factor XIIa. The rPLTP
concentration was 0 (○) or 5 μg/ml (●). Figure S3. Absence of inhibition by
rPLTP of sulfatide-stimulated factor XII activation by kallikrein or of prekallikrein
activation by factor XIIa in the presence of VLDL in purified system. (A) Time
course of factor XII activation by kallikrein. (B) Time course of prekallikrein
activation by factor XIIa. The rPLTP concentration was 0 (○) or 5 μg/ml (●).
Figure S4. The distribution of PLTP activity in VTE and control subgroups
when patients and controls were stratified as hyperlipidemic (+) and
normolipidemic (-) based on LDL-C levels. The hyperlipidemia group (+) was
defined as subjects who had LDL–C or TG levels that were greater than the
75 percentile of controls.
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